Evidence map›Paper›PMID 39017998›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024

Effect of incremental tazobactam concentrations on the bactericidal activity of piperacillin against ESBL-producing enterobacterales clinical isolates causing bacteraemia.

Marta Palombo, Milo Gatti, Benedetta Secci, Pier Giorgio Cojutti, Federico Pea, Davide Gibellini, Paolo Gaibani

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marta PalomboIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Milo GattiDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Benedetta SecciIRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Pier Giorgio CojuttiDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Federico PeaDepartment of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Davide GibelliniDepartment of Diagnostic and Public Health, Microbiology Section, Verona University, Verona, Italy.
Paolo GaibaniDepartment of Diagnostic and Public Health, Microbiology Section, Verona University, Verona, Italy. paolo.gaibani@univr.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the activity of piperacillin in relation to INCREASING TAZOBACTAM CONCENTRATION against ESBL-producing Enterobacterales collected from patients with bacteraemia. Increasing tazobactam concentration (4, 12 or 24 mg/L) exerted a reduction of piperacillin MICs under the clinical breakpoint in a concentration-dependent manner (0%, 60% and 90% of clinical isolates). Also, activity of piperacillin/tazobactam based at higher achievable serum concentrations (123/14 mg/L) is needed to reduce the bacterial growth in 92% of ESBL-producers. CHANGES IN THE PIPERACILLIN MIC IN RELATION TO INCREASING TAZOBACTAM SUGGEST THAT REALTIME TDM COULD BE USED FOR DRIVEN ANTIMICROBIAL THERAPY WITH PIPERACILLIN/TAZOBACTAM IN BSI DUE TO ESBL STRAINS.

Indexed as

Anti-Bacterial AgentsBacteremiabeta-LactamasesEnterobacteriaceaeEnterobacteriaceae InfectionsMicrobial Sensitivity TestsPiperacillinTazobactamHumansPiperacillin, Tazobactam Drug CombinationAnti-Bacterial Agentsbeta-LactamasesPiperacillinPiperacillin, Tazobactam Drug CombinationTazobactamCarbapenem-sparing regimensESBL-producing EnterobacterialesPiperacillin/tazobactam activityPK/PDRealtime therapeutic drug monitoring

Identifiers

PMID39017998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.